4 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine TumorNeoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, colorectal neuroendocrine tumor G1, gastric neuroendocrine tumor G1, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumorActive, not recruitingPhase 32026-10-01NCT00569127
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancerbreast adenocarcinomaActive, not recruitingPhase 32026-10-01NCT00433511
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple MyelomaDS Stage I Multiple Myeloma; DS Stage II Multiple Myeloma; DS Stage III Multiple MyelomaActive, not recruitingPhase 32026-07-29NCT00644228
Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node DissectionNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 32026-04-21NCT03927027